Aminophylline

證據等級: L5

預測適應症: 10 個

Aminophylline: From Bronchospasm to Migraine Disorder

One-Sentence Summary

Aminophylline is a classical methylxanthine compound, widely used as a bronchodilator for asthma, COPD, and apnea of prematurity. The TxGNN model predicts it may be effective for Migraine Disorder, with 0 clinical trials and 6 publications currently supporting this direction — primarily through its adenosine receptor antagonist mechanism.

Quick Overview

Item	Content
Original Indication	Bronchospasm and reversible airway obstruction (asthma, COPD, apnea of prematurity)
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.88%
Evidence Level	L3
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on well-established pharmacology, Aminophylline is a methylxanthine compound whose primary mechanisms include: (1) adenosine receptor antagonism (A1 and A2A subtypes) and (2) non-selective phosphodiesterase (PDE) inhibition, which raises intracellular cAMP levels and relaxes smooth muscle. These properties underpin its bronchodilatory and respiratory-stimulant effects in asthma and apnea of prematurity.

The link to migraine is mechanistically compelling. Accumulating evidence indicates that pathologically elevated adenosine plays a central role in migraine pathogenesis through three pathways: triggering cortical spreading depression (CSD), inducing intracranial vasodilation via A2A receptors, and directly activating trigeminal nociceptors. By blocking adenosine receptors, aminophylline may theoretically interrupt these cascades and reduce both the intensity and frequency of migraine attacks. A 2023 review (PMID 38059379) explicitly frames migraine as a disorder of impaired brain energy metabolism driven by excess adenosine, positioning aminophylline as a potentially strong therapeutic agent.

Strong indirect clinical evidence comes from observations involving regadenoson (a selective A2A adenosine receptor agonist used in cardiac stress imaging): regadenoson can trigger hemiplegic migraine episodes, and the standard reversal agent is aminophylline or caffeine — both methylxanthine adenosine antagonists. This bidirectional relationship directly demonstrates adenosine’s causal role in migraine and, by extension, aminophylline’s potential therapeutic effect.

Clinical Trial Evidence

Currently no related clinical trials registered for Aminophylline in migraine disorder.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38059379	2023	Review / Clinical Report	Pain Management	Proposes migraine as an adenosine-driven disorder of impaired brain energy metabolism; aminophylline (adenosine receptor antagonist) demonstrated strong therapeutic relief for pain and headache, including post-dural puncture headache, in an observational case series
34308528	2022	Case Report	Journal of Nuclear Cardiology	Regadenoson (A2A adenosine receptor agonist) triggered a hemiplegic migraine episode during cardiac stress imaging; aminophylline reversed the episode — directly demonstrating adenosine’s causal role in migraine and aminophylline’s antagonist effect
219563	1979	Basic Science	Stroke	Adenosine and adenine compounds (AMP, cAMP, ADP, ATP) markedly dilated pial (intracranial) arteries in vitro but not extracranial arteries; establishes the selective intracranial vascular basis for adenosine’s role in migraine pathophysiology
7728647	1995	Case Report	Canadian Journal of Cardiology	Patient with syndrome X developed “myocardial migraine” via excessive adenosine effect; dipyridamole (adenosine-enhancing agent) provoked severe pain without ischemia, further supporting adenosine’s vascular pain signaling role
14168418	1964	Historical Review	Aggiornamenti clinicoterapeutici	Early clinical investigation of pharmacological headache management; historical context only, limited direct evidence
5540199	1971	Formulation	The Practitioner	Discusses suppository formulations; limited direct relevance to migraine indication

Philippines Market Information

Aminophylline currently has no registered products in the Philippines (FDA Philippines). The drug is classified as not marketed, with zero active drug licenses on record. Any clinical development or repurposing program would need to proceed through a full new drug application or compassionate use pathway.

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings, contraindications, and drug-drug interaction data were not retrievable from the current Evidence Pack. Prior to any clinical development, it is essential to obtain the full prescribing information. Aminophylline is known to have a narrow therapeutic index (therapeutic range ~10–20 µg/mL for theophylline), and toxicity risk is clinically relevant for dose escalation decisions.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A biologically plausible and well-articulated adenosine receptor antagonism mechanism directly links aminophylline to migraine pathophysiology, supported by a recent review-level publication and case report evidence. However, no prospective clinical trials have been conducted for this specific indication, and the drug lacks Philippines market registration — meaning the evidence base remains observational and the regulatory pathway is uncharted.

To proceed, the following is needed:

Safety data gap closure: Download and parse the TFDA/FDA Philippines package insert to extract key warnings, contraindications, and known drug interactions — currently a blocking data gap
MOA profile confirmation: Query DrugBank API to obtain the full mechanism of action, drug targets (A1/A2A receptor affinities, PDE isoform selectivity), and pharmacokinetic data
Prospective pilot study: Design and register a Phase 2 proof-of-concept RCT evaluating aminophylline in acute migraine or migraine prevention, using validated outcome measures (MIDAS, headache diary)
Dose-finding work: Establish a migraine-specific dosing regimen; existing bronchodilator dosing may not translate directly due to the narrow therapeutic index
Cardiovascular safety assessment: Evaluate arrhythmia risk and hemodynamic effects in migraine patient populations, especially given known cardiac sensitivities of methylxanthines
Philippines regulatory pathway: Consult FDA Philippines on the registration requirements for a repurposed drug currently absent from the market
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.